-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Vl2auVTMclCeJGHeo97IfMB/W5A6v0p9LVu1n8HmYkIiSO0W1TabbNzU4QfWVymg sVbCzue5gqOR3KFDEJ7aqw== 0000950130-98-000066.txt : 19980109 0000950130-98-000066.hdr.sgml : 19980109 ACCESSION NUMBER: 0000950130-98-000066 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 19980108 ITEM INFORMATION: FILED AS OF DATE: 19980108 SROS: AMEX FILER: COMPANY DATA: COMPANY CONFORMED NAME: ROBERTS PHARMACEUTICAL CORP CENTRAL INDEX KEY: 0000853022 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 222429994 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 001-10432 FILM NUMBER: 98502857 BUSINESS ADDRESS: STREET 1: 4 INDUSTRIAL WAY WEST STREET 2: 4 INDUSTRIAL WAY W CITY: EATONTOWN STATE: NJ ZIP: 07755 BUSINESS PHONE: 7323891182 MAIL ADDRESS: STREET 1: 4 INDUSTRIAL WAY WEST STREET 2: 4 INDUSTRIAL WAY WEST CITY: EATONTOWN STATE: NJ ZIP: 07755 8-K 1 FORM 8-K FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 1998 ROBERTS PHARMACEUTICAL CORPORATION - -------------------------------------------------------------------------------- (exact name of registrant as specified in its charter) NEW JERSEY 1-1-432 22-2429994 - ----------------------- ----------------- ---------------------------- (State or other (Commission (IRS Employer jurisdiction of File Number) Identification incorporation Number) Meridian Center II 4 Industrial Way West Eatontown, New Jersey 07724 - -------------------------------------------------------------------------------- (Address of principal executive offices, including zip code) Registrant's telephone number, including area code: 732-389-1182 Meridian Center II 4 Industrial Way West Eatontown, New Jersey 07724 - -------------------------------------------------------------------------------- (Former name or former address, if changed from last report) -2- Item 5. Other Events ------------ Roberts Pharmaceutical Corporation announced today that it has submitted a regulatory application in the U.S. for approval to expand the current indication for Agrylin/TM/ (anagrelide hydrochloride) to include polycythemia vera, a chronic myeloproliferative disorder where an increase in blood platelets is present. In March 1997, the Company introduced and began marketing Agrylin/TM/ in the United States as it was one of the Company's first FDA cleared drugs. The current approved indication for Agrylin/TM/ is to treat essential thrombocythemia. Separately, a Product License Application has been filed with the Medicines Control Agency in the United Kingdom seeking approval to market ProAmatine/R/ (midodrine hydrochloride) for the treatment of orthostatic hypotension. The application was submitted by Monmouth Pharmaceuticals, Ltd., a wholly owned subsidiary of Roberts located in Guildford, England. ProAmatine/R/ is currently being marketed by Monmouth Pharmaceuticals, Ltd. in Ireland where it is sold under the name Midon/R/ for treatment of orthostatic hypotension. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ROBERTS PHARMACEUTICAL CORPORATION ---------------------------------- (Registrant) Date: January 8, 1998 By: /s/ Anthony A. Rascio ------------------------------ Anthony A. Rasio Vice President -----END PRIVACY-ENHANCED MESSAGE-----